Smokeless tobacco alternatives company Black Buffalo Inc announced on Tuesday that it has partnered with Sanova LLC, a New York-based scientific and regulatory consulting agency, to support its regulatory, compliance, and scientific research programmes.
Sanova has extensive experience helping nicotine manufacturers navigate complex regulatory frameworks, including the US Food and Drug Administration's (FDA) Premarket Tobacco Product Application (PMTA) and Modified Risk Tobacco Product (MRTP) pathways. Sanova's partnership with Black Buffalo includes helping guide the company through the final and most critical phases of FDA review, including substantive scientific review, a rigorous process that evaluates the health impact and overall safety profile of nicotine products intended for adult use.
Kellsi Booth, Black Buffalo's chief legal officer, said: "The Sanova team combines decades of FDA and industry insight with a forward-looking approach. Enlisting Sanova as a key partner represents our commitment to full regulatory transparency, scientific excellence, and responsible innovation within the nicotine space."
Sobi s Aspaveli marketing authorisation receives positive European regulatory opinion
BioCryst wins FDA approval for oral HAE prophylaxis in young children
NanOlogy launches drug development program for diffuse intrinsic pontine glioma treatment
Amgen's UPLIZNA receives US FDA approval
FDA grants priority review to Bristol Myers Squibb's Opdivo regimen for advanced Hodgkin lymphoma
Zydus Lifesciences enters licence and supply partnership with Formycon
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
J & D Pharmaceuticals' investigational therapy for HCC receives US FDA Orphan Drug Designation